Trial Profile
A Phase 1/2, Open-Label, Dose-Escalation And Expansion Study Of Entrectinib (Rxdx-101) In Pediatrics With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 27 Feb 2024
Price :
$35
*
At a glance
- Drugs Entrectinib (Primary)
- Indications CNS cancer; Neuroblastoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms STARTRK-NG
- Sponsors Roche
- 22 Feb 2024 Planned primary completion date changed to 15 Jun 2025.
- 01 Mar 2023 Results(n=43) assessing the pharmacokinetics of entrectinib and its active metabolite (M5) in pediatric patients published in the Cancer Chemotherapy and Pharmacology
- 13 Jan 2023 Planned End Date changed from 30 Aug 2027 to 15 Jun 2025.